Cargando…

Inter‐observer agreement for the histological diagnosis of invasive lobular breast carcinoma

Invasive lobular breast carcinoma (ILC) is the second most common breast carcinoma (BC) subtype and is mainly driven by loss of E‐cadherin expression. Correct classification of BC as ILC is important for patient treatment. This study assessed the degree of agreement among pathologists for the diagno...

Descripción completa

Detalles Bibliográficos
Autores principales: Christgen, Matthias, Kandt, Leonie Donata, Antonopoulos, Wiebke, Bartels, Stephan, Van Bockstal, Mieke R, Bredt, Martin, Brito, Maria Jose, Christgen, Henriette, Colpaert, Cecile, Cserni, Bálint, Cserni, Gábor, Daemmrich, Maximilian E, Danebrock, Raihanatou, Dedeurwaerdere, Franceska, van Deurzen, Carolien HM, Erber, Ramona, Fathke, Christine, Feist, Henning, Fiche, Maryse, Gonzalez, Claudia Aura, ter Hoeve, Natalie D, Kooreman, Loes, Krech, Till, Kristiansen, Glen, Kulka, Janina, Laenger, Florian, Lafos, Marcel, Lehmann, Ulrich, Martin‐Martinez, Maria Dolores, Mueller, Sophie, Pelz, Enrico, Raap, Mieke, Ravarino, Alberto, Reineke‐Plaass, Tanja, Schaumann, Nora, Schelfhout, Anne‐Marie, De Schepper, Maxim, Schlue, Jerome, Van de Vijver, Koen, Waelput, Wim, Wellmann, Axel, Graeser, Monika, Gluz, Oleg, Kuemmel, Sherko, Nitz, Ulrike, Harbeck, Nadia, Desmedt, Christine, Floris, Giuseppe, Derksen, Patrick WB, van Diest, Paul J, Vincent‐Salomon, Anne, Kreipe, Hans
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8822373/
https://www.ncbi.nlm.nih.gov/pubmed/34889530
http://dx.doi.org/10.1002/cjp2.253
_version_ 1784646595348791296
author Christgen, Matthias
Kandt, Leonie Donata
Antonopoulos, Wiebke
Bartels, Stephan
Van Bockstal, Mieke R
Bredt, Martin
Brito, Maria Jose
Christgen, Henriette
Colpaert, Cecile
Cserni, Bálint
Cserni, Gábor
Daemmrich, Maximilian E
Danebrock, Raihanatou
Dedeurwaerdere, Franceska
van Deurzen, Carolien HM
Erber, Ramona
Fathke, Christine
Feist, Henning
Fiche, Maryse
Gonzalez, Claudia Aura
ter Hoeve, Natalie D
Kooreman, Loes
Krech, Till
Kristiansen, Glen
Kulka, Janina
Laenger, Florian
Lafos, Marcel
Lehmann, Ulrich
Martin‐Martinez, Maria Dolores
Mueller, Sophie
Pelz, Enrico
Raap, Mieke
Ravarino, Alberto
Reineke‐Plaass, Tanja
Schaumann, Nora
Schelfhout, Anne‐Marie
De Schepper, Maxim
Schlue, Jerome
Van de Vijver, Koen
Waelput, Wim
Wellmann, Axel
Graeser, Monika
Gluz, Oleg
Kuemmel, Sherko
Nitz, Ulrike
Harbeck, Nadia
Desmedt, Christine
Floris, Giuseppe
Derksen, Patrick WB
van Diest, Paul J
Vincent‐Salomon, Anne
Kreipe, Hans
author_facet Christgen, Matthias
Kandt, Leonie Donata
Antonopoulos, Wiebke
Bartels, Stephan
Van Bockstal, Mieke R
Bredt, Martin
Brito, Maria Jose
Christgen, Henriette
Colpaert, Cecile
Cserni, Bálint
Cserni, Gábor
Daemmrich, Maximilian E
Danebrock, Raihanatou
Dedeurwaerdere, Franceska
van Deurzen, Carolien HM
Erber, Ramona
Fathke, Christine
Feist, Henning
Fiche, Maryse
Gonzalez, Claudia Aura
ter Hoeve, Natalie D
Kooreman, Loes
Krech, Till
Kristiansen, Glen
Kulka, Janina
Laenger, Florian
Lafos, Marcel
Lehmann, Ulrich
Martin‐Martinez, Maria Dolores
Mueller, Sophie
Pelz, Enrico
Raap, Mieke
Ravarino, Alberto
Reineke‐Plaass, Tanja
Schaumann, Nora
Schelfhout, Anne‐Marie
De Schepper, Maxim
Schlue, Jerome
Van de Vijver, Koen
Waelput, Wim
Wellmann, Axel
Graeser, Monika
Gluz, Oleg
Kuemmel, Sherko
Nitz, Ulrike
Harbeck, Nadia
Desmedt, Christine
Floris, Giuseppe
Derksen, Patrick WB
van Diest, Paul J
Vincent‐Salomon, Anne
Kreipe, Hans
author_sort Christgen, Matthias
collection PubMed
description Invasive lobular breast carcinoma (ILC) is the second most common breast carcinoma (BC) subtype and is mainly driven by loss of E‐cadherin expression. Correct classification of BC as ILC is important for patient treatment. This study assessed the degree of agreement among pathologists for the diagnosis of ILC. Two sets of hormone receptor (HR)‐positive/HER2‐negative BCs were independently reviewed by participating pathologists. In set A (61 cases), participants were provided with hematoxylin/eosin (HE)‐stained sections. In set B (62 cases), participants were provided with HE‐stained sections and E‐cadherin immunohistochemistry (IHC). Tumor characteristics were balanced. Participants classified specimens as non‐lobular BC versus mixed BC versus ILC. Pairwise inter‐observer agreement and agreement with a pre‐defined reference diagnosis were determined with Cohen's kappa statistics. Subtype calls were correlated with molecular features, including CDH1/E‐cadherin mutation status. Thirty‐five pathologists completed both sets, providing 4,305 subtype calls. Pairwise inter‐observer agreement was moderate in set A (median κ = 0.58, interquartile range [IQR]: 0.48–0.66) and substantial in set B (median κ = 0.75, IQR: 0.56–0.86, p < 0.001). Agreement with the reference diagnosis was substantial in set A (median κ = 0.67, IQR: 0.57–0.75) and almost perfect in set B (median κ = 0.86, IQR: 0.73–0.93, p < 0.001). The median frequency of CDH1/E‐cadherin mutations in specimens classified as ILC was 65% in set A (IQR: 56–72%) and 73% in set B (IQR: 65–75%, p < 0.001). Cases with variable subtype calls included E‐cadherin‐positive ILCs harboring CDH1 missense mutations, and E‐cadherin‐negative ILCs with tubular elements and focal P‐cadherin expression. ILCs with trabecular growth pattern were often misclassified as non‐lobular BC in set A but not in set B. In conclusion, subtyping of BC as ILC achieves almost perfect agreement with a pre‐defined reference standard, if assessment is supported by E‐cadherin IHC. CDH1 missense mutations associated with preserved E‐cadherin protein expression, E‐ to P‐cadherin switching in ILC with tubular elements, and trabecular ILC were identified as potential sources of discordant classification.
format Online
Article
Text
id pubmed-8822373
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley & Sons, Inc.
record_format MEDLINE/PubMed
spelling pubmed-88223732022-02-11 Inter‐observer agreement for the histological diagnosis of invasive lobular breast carcinoma Christgen, Matthias Kandt, Leonie Donata Antonopoulos, Wiebke Bartels, Stephan Van Bockstal, Mieke R Bredt, Martin Brito, Maria Jose Christgen, Henriette Colpaert, Cecile Cserni, Bálint Cserni, Gábor Daemmrich, Maximilian E Danebrock, Raihanatou Dedeurwaerdere, Franceska van Deurzen, Carolien HM Erber, Ramona Fathke, Christine Feist, Henning Fiche, Maryse Gonzalez, Claudia Aura ter Hoeve, Natalie D Kooreman, Loes Krech, Till Kristiansen, Glen Kulka, Janina Laenger, Florian Lafos, Marcel Lehmann, Ulrich Martin‐Martinez, Maria Dolores Mueller, Sophie Pelz, Enrico Raap, Mieke Ravarino, Alberto Reineke‐Plaass, Tanja Schaumann, Nora Schelfhout, Anne‐Marie De Schepper, Maxim Schlue, Jerome Van de Vijver, Koen Waelput, Wim Wellmann, Axel Graeser, Monika Gluz, Oleg Kuemmel, Sherko Nitz, Ulrike Harbeck, Nadia Desmedt, Christine Floris, Giuseppe Derksen, Patrick WB van Diest, Paul J Vincent‐Salomon, Anne Kreipe, Hans J Pathol Clin Res Original Articles Invasive lobular breast carcinoma (ILC) is the second most common breast carcinoma (BC) subtype and is mainly driven by loss of E‐cadherin expression. Correct classification of BC as ILC is important for patient treatment. This study assessed the degree of agreement among pathologists for the diagnosis of ILC. Two sets of hormone receptor (HR)‐positive/HER2‐negative BCs were independently reviewed by participating pathologists. In set A (61 cases), participants were provided with hematoxylin/eosin (HE)‐stained sections. In set B (62 cases), participants were provided with HE‐stained sections and E‐cadherin immunohistochemistry (IHC). Tumor characteristics were balanced. Participants classified specimens as non‐lobular BC versus mixed BC versus ILC. Pairwise inter‐observer agreement and agreement with a pre‐defined reference diagnosis were determined with Cohen's kappa statistics. Subtype calls were correlated with molecular features, including CDH1/E‐cadherin mutation status. Thirty‐five pathologists completed both sets, providing 4,305 subtype calls. Pairwise inter‐observer agreement was moderate in set A (median κ = 0.58, interquartile range [IQR]: 0.48–0.66) and substantial in set B (median κ = 0.75, IQR: 0.56–0.86, p < 0.001). Agreement with the reference diagnosis was substantial in set A (median κ = 0.67, IQR: 0.57–0.75) and almost perfect in set B (median κ = 0.86, IQR: 0.73–0.93, p < 0.001). The median frequency of CDH1/E‐cadherin mutations in specimens classified as ILC was 65% in set A (IQR: 56–72%) and 73% in set B (IQR: 65–75%, p < 0.001). Cases with variable subtype calls included E‐cadherin‐positive ILCs harboring CDH1 missense mutations, and E‐cadherin‐negative ILCs with tubular elements and focal P‐cadherin expression. ILCs with trabecular growth pattern were often misclassified as non‐lobular BC in set A but not in set B. In conclusion, subtyping of BC as ILC achieves almost perfect agreement with a pre‐defined reference standard, if assessment is supported by E‐cadherin IHC. CDH1 missense mutations associated with preserved E‐cadherin protein expression, E‐ to P‐cadherin switching in ILC with tubular elements, and trabecular ILC were identified as potential sources of discordant classification. John Wiley & Sons, Inc. 2021-12-10 /pmc/articles/PMC8822373/ /pubmed/34889530 http://dx.doi.org/10.1002/cjp2.253 Text en © 2021 The Authors. The Journal of Pathology: Clinical Research published by The Pathological Society of Great Britain and Ireland & John Wiley & Sons, Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Articles
Christgen, Matthias
Kandt, Leonie Donata
Antonopoulos, Wiebke
Bartels, Stephan
Van Bockstal, Mieke R
Bredt, Martin
Brito, Maria Jose
Christgen, Henriette
Colpaert, Cecile
Cserni, Bálint
Cserni, Gábor
Daemmrich, Maximilian E
Danebrock, Raihanatou
Dedeurwaerdere, Franceska
van Deurzen, Carolien HM
Erber, Ramona
Fathke, Christine
Feist, Henning
Fiche, Maryse
Gonzalez, Claudia Aura
ter Hoeve, Natalie D
Kooreman, Loes
Krech, Till
Kristiansen, Glen
Kulka, Janina
Laenger, Florian
Lafos, Marcel
Lehmann, Ulrich
Martin‐Martinez, Maria Dolores
Mueller, Sophie
Pelz, Enrico
Raap, Mieke
Ravarino, Alberto
Reineke‐Plaass, Tanja
Schaumann, Nora
Schelfhout, Anne‐Marie
De Schepper, Maxim
Schlue, Jerome
Van de Vijver, Koen
Waelput, Wim
Wellmann, Axel
Graeser, Monika
Gluz, Oleg
Kuemmel, Sherko
Nitz, Ulrike
Harbeck, Nadia
Desmedt, Christine
Floris, Giuseppe
Derksen, Patrick WB
van Diest, Paul J
Vincent‐Salomon, Anne
Kreipe, Hans
Inter‐observer agreement for the histological diagnosis of invasive lobular breast carcinoma
title Inter‐observer agreement for the histological diagnosis of invasive lobular breast carcinoma
title_full Inter‐observer agreement for the histological diagnosis of invasive lobular breast carcinoma
title_fullStr Inter‐observer agreement for the histological diagnosis of invasive lobular breast carcinoma
title_full_unstemmed Inter‐observer agreement for the histological diagnosis of invasive lobular breast carcinoma
title_short Inter‐observer agreement for the histological diagnosis of invasive lobular breast carcinoma
title_sort inter‐observer agreement for the histological diagnosis of invasive lobular breast carcinoma
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8822373/
https://www.ncbi.nlm.nih.gov/pubmed/34889530
http://dx.doi.org/10.1002/cjp2.253
work_keys_str_mv AT christgenmatthias interobserveragreementforthehistologicaldiagnosisofinvasivelobularbreastcarcinoma
AT kandtleoniedonata interobserveragreementforthehistologicaldiagnosisofinvasivelobularbreastcarcinoma
AT antonopouloswiebke interobserveragreementforthehistologicaldiagnosisofinvasivelobularbreastcarcinoma
AT bartelsstephan interobserveragreementforthehistologicaldiagnosisofinvasivelobularbreastcarcinoma
AT vanbockstalmieker interobserveragreementforthehistologicaldiagnosisofinvasivelobularbreastcarcinoma
AT bredtmartin interobserveragreementforthehistologicaldiagnosisofinvasivelobularbreastcarcinoma
AT britomariajose interobserveragreementforthehistologicaldiagnosisofinvasivelobularbreastcarcinoma
AT christgenhenriette interobserveragreementforthehistologicaldiagnosisofinvasivelobularbreastcarcinoma
AT colpaertcecile interobserveragreementforthehistologicaldiagnosisofinvasivelobularbreastcarcinoma
AT csernibalint interobserveragreementforthehistologicaldiagnosisofinvasivelobularbreastcarcinoma
AT csernigabor interobserveragreementforthehistologicaldiagnosisofinvasivelobularbreastcarcinoma
AT daemmrichmaximiliane interobserveragreementforthehistologicaldiagnosisofinvasivelobularbreastcarcinoma
AT danebrockraihanatou interobserveragreementforthehistologicaldiagnosisofinvasivelobularbreastcarcinoma
AT dedeurwaerderefranceska interobserveragreementforthehistologicaldiagnosisofinvasivelobularbreastcarcinoma
AT vandeurzencarolienhm interobserveragreementforthehistologicaldiagnosisofinvasivelobularbreastcarcinoma
AT erberramona interobserveragreementforthehistologicaldiagnosisofinvasivelobularbreastcarcinoma
AT fathkechristine interobserveragreementforthehistologicaldiagnosisofinvasivelobularbreastcarcinoma
AT feisthenning interobserveragreementforthehistologicaldiagnosisofinvasivelobularbreastcarcinoma
AT fichemaryse interobserveragreementforthehistologicaldiagnosisofinvasivelobularbreastcarcinoma
AT gonzalezclaudiaaura interobserveragreementforthehistologicaldiagnosisofinvasivelobularbreastcarcinoma
AT terhoevenatalied interobserveragreementforthehistologicaldiagnosisofinvasivelobularbreastcarcinoma
AT kooremanloes interobserveragreementforthehistologicaldiagnosisofinvasivelobularbreastcarcinoma
AT krechtill interobserveragreementforthehistologicaldiagnosisofinvasivelobularbreastcarcinoma
AT kristiansenglen interobserveragreementforthehistologicaldiagnosisofinvasivelobularbreastcarcinoma
AT kulkajanina interobserveragreementforthehistologicaldiagnosisofinvasivelobularbreastcarcinoma
AT laengerflorian interobserveragreementforthehistologicaldiagnosisofinvasivelobularbreastcarcinoma
AT lafosmarcel interobserveragreementforthehistologicaldiagnosisofinvasivelobularbreastcarcinoma
AT lehmannulrich interobserveragreementforthehistologicaldiagnosisofinvasivelobularbreastcarcinoma
AT martinmartinezmariadolores interobserveragreementforthehistologicaldiagnosisofinvasivelobularbreastcarcinoma
AT muellersophie interobserveragreementforthehistologicaldiagnosisofinvasivelobularbreastcarcinoma
AT pelzenrico interobserveragreementforthehistologicaldiagnosisofinvasivelobularbreastcarcinoma
AT raapmieke interobserveragreementforthehistologicaldiagnosisofinvasivelobularbreastcarcinoma
AT ravarinoalberto interobserveragreementforthehistologicaldiagnosisofinvasivelobularbreastcarcinoma
AT reinekeplaasstanja interobserveragreementforthehistologicaldiagnosisofinvasivelobularbreastcarcinoma
AT schaumannnora interobserveragreementforthehistologicaldiagnosisofinvasivelobularbreastcarcinoma
AT schelfhoutannemarie interobserveragreementforthehistologicaldiagnosisofinvasivelobularbreastcarcinoma
AT descheppermaxim interobserveragreementforthehistologicaldiagnosisofinvasivelobularbreastcarcinoma
AT schluejerome interobserveragreementforthehistologicaldiagnosisofinvasivelobularbreastcarcinoma
AT vandevijverkoen interobserveragreementforthehistologicaldiagnosisofinvasivelobularbreastcarcinoma
AT waelputwim interobserveragreementforthehistologicaldiagnosisofinvasivelobularbreastcarcinoma
AT wellmannaxel interobserveragreementforthehistologicaldiagnosisofinvasivelobularbreastcarcinoma
AT graesermonika interobserveragreementforthehistologicaldiagnosisofinvasivelobularbreastcarcinoma
AT gluzoleg interobserveragreementforthehistologicaldiagnosisofinvasivelobularbreastcarcinoma
AT kuemmelsherko interobserveragreementforthehistologicaldiagnosisofinvasivelobularbreastcarcinoma
AT nitzulrike interobserveragreementforthehistologicaldiagnosisofinvasivelobularbreastcarcinoma
AT harbecknadia interobserveragreementforthehistologicaldiagnosisofinvasivelobularbreastcarcinoma
AT desmedtchristine interobserveragreementforthehistologicaldiagnosisofinvasivelobularbreastcarcinoma
AT florisgiuseppe interobserveragreementforthehistologicaldiagnosisofinvasivelobularbreastcarcinoma
AT derksenpatrickwb interobserveragreementforthehistologicaldiagnosisofinvasivelobularbreastcarcinoma
AT vandiestpaulj interobserveragreementforthehistologicaldiagnosisofinvasivelobularbreastcarcinoma
AT vincentsalomonanne interobserveragreementforthehistologicaldiagnosisofinvasivelobularbreastcarcinoma
AT kreipehans interobserveragreementforthehistologicaldiagnosisofinvasivelobularbreastcarcinoma